NCT03673332View on ClinicalTrials.gov

Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 16, 2019

Primary Completion Date

July 15, 2025

Study Completion Date

July 15, 2025

Conditions
Advanced or Metastatic MelanomaAdvanced or Metastatic NSCLC
Interventions
DRUG

immune-checkpoint inhibitors therapies

All patients included in this study will receive approved immune-checkpoint inhibitors therapies, such as CTLA-4, PD-1, and PD-L1 inhibitors.

Trial Locations (9)

13009

Institut Paoli-Calmettes, Marseille

13385

Assistance Publique des Hôpitaux de Marseille, Marseille

21079

Centre Georges François Leclerc, Dijon

34298

Institut Du Cancer de Montpellier, Montpellier

Unknown

Institut BERGONIE, Bordeaux

CENTRE Francois Baclesse, Caen

Institut Curie, Paris

Institut De Cancérologie de l'Ouest, Saint-Herblain

IUCT-Oncopole Institut Claudius Rigaud, Toulouse

All Listed Sponsors
collaborator

Société Francophone d'Onco-Gériatrie

OTHER

lead

Institut Paoli-Calmettes

OTHER